Collectively, these VISTA-targeted therapies highlight a broad spectrum of immunomodulatory strategies, from epitope-specific antibody blockade and Fc-engineering to pH-conditioned selectivity and orally bioavailable dual checkpoint inhibition, offering versatile platforms to disrupt VISTA-mediated immune escape in cancer. The gene discussed is VSIR; the disease is cancer.